Next-gen oncology: the role of CAR-T cells against ocular lymphoma and myeloma

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS

ACS Applied Bio Materials Pub Date : 2024-09-12 DOI:10.1038/s41433-024-03324-6

Mouayad Masalkhi, Noura Wahhoud, Ezzat Elhassadi

{"title":"Next-gen oncology: the role of CAR-T cells against ocular lymphoma and myeloma","authors":"Mouayad Masalkhi, Noura Wahhoud, Ezzat Elhassadi","doi":"10.1038/s41433-024-03324-6","DOIUrl":null,"url":null,"abstract":"<p>Chimeric Antigen Receptor (CAR-T) cell therapy represents a groundbreaking advancement in the field of cancer immunotherapy, where it offers a highly targeted and personalized approach to cancer treatment [1]. Since its birth in 1993, this innovative therapy has been built upon the genetic engineering of a patient’s own T cells to express a chimeric antigen receptor (CAR), which is designed to recognize and bind to specific antigens present on cancer cells [1]. By reprogramming the immune system to better recognize and destroy malignant cells, CAR-T therapy improves the body's natural ability to fight cancer cells with unprecedented precision and effectiveness [1].</p><p>The therapeutic potential of CAR-T cells has been particularly promising in the treatment of hematological malignancies, such as lymphoma and multiple myeloma (MM) [2]. The ability to specifically target antigens, such as CD19 in B cell malignancies, CD20 in lymphomas, and CD138 in MM, allows for a more directed and efficient immune response and significantly reduces the off-target effects that often accompany traditional cancer treatments like chemotherapy or radiation [2, 3].</p>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41433-024-03324-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Chimeric Antigen Receptor (CAR-T) cell therapy represents a groundbreaking advancement in the field of cancer immunotherapy, where it offers a highly targeted and personalized approach to cancer treatment [1]. Since its birth in 1993, this innovative therapy has been built upon the genetic engineering of a patient’s own T cells to express a chimeric antigen receptor (CAR), which is designed to recognize and bind to specific antigens present on cancer cells [1]. By reprogramming the immune system to better recognize and destroy malignant cells, CAR-T therapy improves the body's natural ability to fight cancer cells with unprecedented precision and effectiveness [1].

The therapeutic potential of CAR-T cells has been particularly promising in the treatment of hematological malignancies, such as lymphoma and multiple myeloma (MM) [2]. The ability to specifically target antigens, such as CD19 in B cell malignancies, CD20 in lymphomas, and CD138 in MM, allows for a more directed and efficient immune response and significantly reduces the off-target effects that often accompany traditional cancer treatments like chemotherapy or radiation [2, 3].

查看原文本刊更多论文

新一代肿瘤学：CAR-T 细胞对眼部淋巴瘤和骨髓瘤的作用

嵌合抗原受体（CAR-T）细胞疗法是癌症免疫疗法领域的突破性进展，它提供了一种高度靶向性和个性化的癌症治疗方法[1]。自 1993 年诞生以来，这种创新疗法一直建立在对患者自身的 T 细胞进行基因工程改造，使其表达嵌合抗原受体 (CAR)，从而识别并结合癌细胞上的特定抗原[1]。通过对免疫系统进行重新编程，使其能更好地识别和消灭恶性细胞，CAR-T疗法以前所未有的精确性和有效性提高了机体对抗癌细胞的自然能力[1]。CAR-T细胞的治疗潜力在治疗淋巴瘤和多发性骨髓瘤（MM）等血液恶性肿瘤方面尤其具有前景[2]。CAR-T 细胞能够特异性地靶向抗原，如 B 细胞恶性肿瘤中的 CD19、淋巴瘤中的 CD20 和 MM 中的 CD138，从而产生更有针对性、更有效的免疫反应，并显著减少化疗或放疗等传统癌症治疗方法经常产生的脱靶效应[2, 3]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464